Nifty
Sensex
:
:
9915.25
32028.89
41.95 (0.42%)
124.49 (0.39%)

Pharmaceuticals & Drugs

Rating :
40/99

BSE: 500087 | NSE: CIPLA

566.20
-5.70 (-1.00%)
21-Jul-2017 | 3:54PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 570.00
  • 570.00
  • 560.15
  • 571.90
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  • 672906
  • 3809.99
  • 621.25
  • 480.20

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 45,995.12
  • 45.70
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,483.57
  • 0.35%
  • 3.69

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 37.48%
  • 3.75%
  • 18.32%
  • FII
  • DII
  • Others
  • 2.51%
  • 15.5%
  • 22.44%

Chart

Price | P:E | P:BV | EV:EBITDA

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Var%
Dec 16
Dec 15
Var%
Sep 16
Sep 15
Var%
Jun 16
Jun 15
Var%
Net Sales
3,582.00
3,266.54
9.66%
3,647.21
3,106.55
17.40%
3,751.02
3,452.41
8.65%
3,593.72
3,852.77
-6.72%
Expenses
3,075.76
3,047.58
0.92%
2,969.56
2,652.84
11.94%
3,070.31
2,663.01
15.29%
2,982.75
2,813.78
6.01%
EBITDA
506.24
218.96
131.20%
677.65
453.71
49.36%
680.71
789.40
-13.77%
610.97
1,038.99
-41.20%
EBIDTM
14.13%
6.70%
18.58%
14.60%
18.15%
22.87%
17.00%
26.97%
Other Income
22.79
54.74
-58.37%
153.49
79.30
93.56%
27.23
25.92
5.05%
25.20
48.93
-48.50%
Interest
33.40
36.76
-9.14%
59.33
22.95
158.52%
35.16
50.27
-30.06%
31.34
51.36
-38.98%
Depreciation
632.19
141.43
347.00%
257.74
137.47
87.49%
229.18
133.96
71.08%
160.81
128.79
24.86%
PBT
-136.56
95.51
-
514.07
372.59
37.97%
443.60
631.09
-29.71%
444.02
907.77
-51.09%
Tax
-75.70
-3.90
-
128.27
11.97
971.60%
71.90
181.24
-60.33%
70.81
250.28
-71.71%
PAT
-60.86
99.41
-
385.80
360.62
6.98%
371.70
449.85
-17.37%
373.21
657.49
-43.24%
PATM
-1.70%
3.04%
10.58%
11.61%
9.91%
13.03%
10.39%
17.07%
EPS
-0.77
1.01
-
4.66
4.27
9.13%
4.41
5.37
-17.88%
4.54
8.10
-43.95%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Net Sales
14,394.29
13,678.27
11,345.44
10,173.39
8,279.33
7,020.71
6,323.84
5,359.52
4,960.60
4,010.38
Net Sales Growth
5.23%
20.56%
11.52%
22.88%
17.93%
11.02%
17.99%
8.04%
23.69%
 
Cost Of Goods Sold
5,317.12
5,133.24
4,270.63
3,874.83
2,952.61
2,739.30
2,775.18
2,452.98
2,347.40
2,054.39
Gross Profit
9,077.17
8,545.03
7,074.81
6,298.56
5,326.72
4,281.41
3,548.66
2,906.54
2,613.20
1,955.99
GP Margin
63.06%
62.47%
62.36%
61.91%
64.34%
60.98%
56.12%
54.23%
52.68%
48.77%
Total Expenditure
11,918.50
11,177.21
9,183.74
8,040.34
6,081.48
5,361.86
4,954.60
4,286.56
4,215.55
3,377.91
Power & Fuel Cost
251.73
245.92
228.28
218.63
233.12
235.35
198.55
92.15
91.71
74.69
% Of Sales
1.75%
1.80%
2.01%
2.15%
2.82%
3.35%
3.14%
1.72%
1.85%
1.86%
Employee Cost
2,633.82
2,447.06
1,967.72
1,542.96
1,036.02
772.50
565.59
289.59
242.91
186.47
% Of Sales
18.30%
17.89%
17.34%
15.17%
12.51%
11.00%
8.94%
5.40%
4.90%
4.65%
Manufacturing Exp.
1,704.79
1,023.49
737.11
644.42
541.58
583.18
627.94
708.39
676.85
509.42
% Of Sales
11.84%
7.48%
6.50%
6.33%
6.54%
8.31%
9.93%
13.22%
13.64%
12.70%
General & Admin Exp.
868.31
845.89
743.46
638.08
496.81
369.85
288.71
231.05
193.89
221.14
% Of Sales
6.03%
6.18%
6.55%
6.27%
6.00%
5.27%
4.57%
4.31%
3.91%
5.51%
Selling & Distn. Exp.
1,009.21
818.76
738.87
680.32
466.22
467.61
386.67
326.48
339.15
282.21
% Of Sales
7.01%
5.99%
6.51%
6.69%
5.63%
6.66%
6.11%
6.09%
6.84%
7.04%
Miscellaneous Exp.
133.52
662.85
497.67
441.10
355.12
194.07
111.96
185.92
323.64
282.21
% Of Sales
0.93%
4.85%
4.39%
4.34%
4.29%
2.76%
1.77%
3.47%
6.52%
1.24%
EBITDA
2,475.79
2,501.06
2,161.70
2,133.05
2,197.85
1,658.85
1,369.24
1,072.96
745.05
632.47
EBITDA Margin
17.20%
18.28%
19.05%
20.97%
26.55%
23.63%
21.65%
20.02%
15.02%
15.77%
Other Income
228.69
208.89
165.55
265.37
222.14
139.52
91.68
353.50
354.49
339.28
Interest
159.38
161.34
168.29
145.74
33.91
38.34
25.10
28.30
52.23
17.52
Depreciation
1,322.93
541.65
504.71
372.64
330.48
312.22
273.33
167.07
151.79
116.26
PBT
1,222.17
2,006.96
1,654.25
1,880.04
2,055.60
1,447.81
1,162.49
1,231.09
895.52
837.97
Tax
179.76
439.59
400.03
463.38
544.31
306.51
195.22
243.50
124.50
136.93
Tax Rate
14.71%
21.90%
24.18%
24.65%
25.98%
21.17%
16.79%
18.36%
13.90%
16.34%
PAT
1,013.38
1,517.94
1,206.07
1,400.73
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
PAT before Minority Interest
1,042.41
1,567.37
1,254.22
1,416.66
1,551.06
1,141.30
967.27
1,082.59
771.02
701.04
Minority Interest
-29.03
-49.43
-48.15
-15.93
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
7.04%
11.10%
10.63%
13.77%
18.73%
16.26%
15.30%
20.20%
15.54%
17.48%
PAT Growth
-33.24%
25.86%
-13.90%
-9.69%
35.90%
17.99%
-10.65%
40.41%
9.98%
 
Unadjusted EPS
12.52
18.76
14.71
17.29
19.24
14.25
12.32
13.70
9.92
9.02

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Shareholder's Funds
12,525.42
11,857.42
10,801.49
10,050.35
9,018.68
7,638.93
6,666.13
5,910.57
4,347.80
3,755.17
Share Capital
160.90
160.68
160.59
160.58
160.58
160.58
160.58
160.58
155.46
155.46
Total Reserves
12,302.48
11,611.73
10,557.74
9,868.12
8,858.10
7,478.35
6,505.55
5,749.99
4,192.34
3,599.71
Non-Current Liabilities
4,513.35
2,568.10
2,417.66
2,028.05
1,024.96
824.27
697.34
184.22
1,104.39
689.60
Secured Loans
0.00
207.00
287.09
317.44
0.00
0.00
15.00
0.41
2.79
14.09
Unsecured Loans
3,645.36
14.88
22.19
0.43
0.55
3.25
2.92
4.66
937.45
526.36
Long Term Provisions
140.52
1,937.04
1,783.17
1,368.64
713.87
557.78
466.30
0.00
0.00
0.00
Current Liabilities
3,308.07
7,908.89
3,881.13
2,563.58
2,277.63
1,413.19
1,698.54
2,525.63
2,112.37
1,287.80
Trade Payables
1,571.14
1,409.49
1,452.06
979.53
828.36
691.77
720.88
805.41
757.43
533.51
Other Current Liabilities
923.79
1,023.79
654.55
408.67
250.89
489.93
235.28
192.56
255.44
337.48
Short Term Borrowings
467.23
4,969.51
1,392.48
910.47
966.38
10.20
523.06
0.00
0.00
0.00
Short Term Provisions
345.91
506.10
382.04
264.91
232.00
221.29
219.32
1,527.66
1,099.50
416.81
Total Liabilities
20,785.07
22,604.04
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57
Net Block
9,472.00
10,269.33
6,829.64
6,496.47
3,609.97
3,215.49
3,094.18
2,011.17
1,992.49
1,661.36
Gross Block
11,305.32
13,608.32
9,561.55
8,676.27
5,317.52
4,626.35
4,240.55
2,897.26
2,693.29
2,201.79
Accumulated Depreciation
1,580.49
3,338.99
2,731.91
2,179.80
1,707.55
1,410.86
1,146.37
886.09
700.80
540.43
Non Current Assets
11,979.00
13,761.86
9,689.47
9,039.59
5,537.29
4,819.58
4,618.88
2,696.41
2,359.84
1,898.51
Capital Work in Progress
1,682.98
809.31
580.90
441.84
377.79
371.17
285.34
684.24
366.32
233.12
Non Current Investment
137.36
176.36
249.76
397.14
415.69
328.59
367.18
1.00
1.03
4.03
Long Term Loans & Adv.
477.35
2,330.01
1,860.78
1,552.40
978.96
865.38
841.20
0.00
0.00
0.00
Other Non Current Assets
209.31
176.85
168.39
151.74
154.88
38.95
30.98
0.00
0.00
0.00
Current Assets
8,806.07
8,842.18
7,591.29
5,651.97
6,783.98
5,056.81
4,443.13
5,924.01
5,204.72
3,834.06
Current Investments
837.39
580.56
390.02
311.43
2,116.75
940.52
223.59
245.41
79.02
89.45
Inventories
3,485.28
3,808.04
3,780.62
2,895.26
2,387.07
1,850.08
1,906.16
1,512.58
1,398.32
1,120.49
Sundry Debtors
2,497.42
2,359.25
1,997.72
1,638.89
1,668.84
1,553.58
1,490.82
1,566.63
1,852.86
1,406.49
Cash & Bank
624.21
871.41
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70
Other Current Assets
1,361.77
261.92
145.60
35.50
468.31
622.17
726.59
2,537.33
1,821.13
1,137.93
Short Term Loans & Adv.
968.64
961.00
713.07
595.13
463.21
459.94
533.77
2,387.57
1,797.68
1,103.44
Net Current Assets
5,498.00
933.29
3,710.16
3,088.39
4,506.35
3,643.62
2,744.59
3,398.38
3,092.35
2,546.26
Total Assets
20,785.07
22,604.04
17,280.76
14,691.56
12,321.27
9,876.39
9,062.01
8,620.42
7,564.56
5,732.57

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Cash From Operating Activity
2,382.37
1,793.87
1,173.43
1,563.31
1,397.67
1,712.76
1,025.10
1,043.03
374.83
367.00
PBT
1,222.17
2,006.96
1,654.25
1,880.04
2,095.38
1,447.81
1,162.49
1,326.09
896.84
837.97
Adjustment
1,379.75
718.83
630.05
552.80
283.82
396.66
288.84
146.53
252.60
104.48
Changes in Working Capital
230.72
-424.23
-718.61
-561.26
-519.84
199.76
-162.03
-173.82
-708.54
-404.47
Cash after chg. in Working capital
2,832.64
2,301.56
1,565.69
1,871.58
1,859.36
2,044.23
1,289.30
1,298.80
440.90
537.98
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-450.27
-507.69
-392.26
-308.27
-461.69
-331.47
-264.20
-255.77
-64.75
-170.98
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,312.65
-4,579.47
-941.15
-1,249.86
-2,062.89
-965.10
-908.39
-562.75
-580.06
-674.41
Net Fixed Assets
1,455.40
-857.19
-534.38
-437.26
-692.52
-460.09
-601.86
-520.07
-624.70
-562.01
Net Investments
570.60
-435.71
-833.97
-985.31
-1,566.67
-464.50
-305.55
-183.78
13.43
23.05
Others
-3,338.65
-3,286.57
427.20
172.71
196.30
-40.51
-0.98
141.10
31.21
-135.45
Cash from Financing Activity
-1,323.85
3,102.68
164.78
-265.63
717.77
-753.17
-82.80
-471.61
178.92
254.83
Net Cash Inflow / Outflow
-254.13
317.08
397.06
47.82
52.55
-5.51
33.91
8.67
-26.31
-52.58
Opening Cash & Equivalents
858.15
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70
132.28
Closing Cash & Equivalent
610.35
871.41
564.26
175.76
143.01
90.46
95.97
62.06
53.39
79.70

Financial Ratios

Consolidated /

Standalone
Description
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Mar 09
Mar 08
Book Value (Rs.)
154.92
146.38
133.38
124.79
112.21
95.03
82.91
73.50
55.82
48.20
ROA
4.98%
7.86%
7.85%
10.49%
13.97%
12.05%
10.94%
13.38%
11.60%
13.82%
ROE
8.73%
13.95%
12.10%
14.89%
18.64%
15.98%
15.40%
21.14%
19.07%
20.11%
ROCE
8.28%
14.68%
15.33%
19.05%
24.15%
19.96%
18.08%
24.22%
19.82%
22.40%
Fixed Asset Turnover
1.36
1.20
1.26
1.47
1.69
1.61
1.79
1.94
2.05
2.05
Receivable days
60.55
57.38
57.94
58.66
70.11
77.94
87.29
115.32
118.45
108.37
Inventory Days
90.98
99.93
106.36
93.68
92.19
96.16
97.61
98.17
91.54
93.41
Payable days
44.80
51.18
52.17
44.93
48.58
50.51
56.11
69.48
59.02
46.55
Cash Conversion Cycle
106.73
106.13
112.14
107.41
113.72
123.59
128.78
144.01
150.98
155.23
Total Debt/Equity
0.33
0.44
0.16
0.12
0.11
0.00
0.09
0.00
0.22
0.14
Interest Cover
8.67
13.44
10.83
13.90
62.79
38.76
47.31
47.86
18.15
48.83

News Update


  • Cipla, Novartis in talk to co-market anti-asthmatic drug Xolair in India: Report
    14th Jul 2017, 11:18 AM

    Xolair (omalizumab) is an injectable prescription medicine used to treat moderate to severe persistent asthma

    Read More
  • Cipla’s arm enters into agreement to sell 99% stake in AJDMA
    9th Jun 2017, 08:58 AM

    The company has entered into an agreement for sale on June 7, 2017

    Read More
  • Cipla concludes divestment of Cipla Vet, Cipla Agrimed
    2nd Jun 2017, 09:43 AM

    Cipla Vet and Cipla Agrimed have ceased to be subsidiaries of Inyanga Trading 386 Proprietary with effect from June 01, 2017

    Read More
  • Cipla - Quarterly Results
    25th May 2017, 12:00 AM

    Read More
  • CARE reaffirms ‘A1+’ rating to Cipla’s short-term bank facilities
    16th May 2017, 10:37 AM

    The company is not availing long-term bank facilities and accordingly the rating for long-term bank facilities has been withdrawn

    Read More
  • Cipla’s arm concludes acquisition of South Africa based Anmarate
    13th Apr 2017, 08:58 AM

    Anmarate is engaged in manufacturing and distribution of pharmaceutical products

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.